New clinical trial has begun in the US to assess the safety and effectiveness of hydroxychloroquine (HCQ) for treating adults hospitalized with COVID-19, according to a release of the National Institutes of Health (NIH) on Thursday. The first participants have enrolled in the trial at Vanderbilt University Medical Center, Tennessee, reported Xinhua news agency.
‘HCQ has proved its effectiveness in lab against the novel Coronavirus. Now clinical trial has started to determine whether it is effective and safe in treating COVID-19 among humans.’
Read More..Tweet it Now
The blinded, placebo-controlled randomized clinical trial aims to enroll more than 500 adults who are currently hospitalized with COVID-19 or in an emergency department with anticipated hospitalization. Read More..
All participants in the study will continue to receive clinical care as indicated for their condition. Those randomized to the experimental intervention will also receive hydroxychloroquine, according to the NIH.
"Effective therapies for COVID-19 are urgently needed," said James Kiley, director of the Division of Lung Diseases of the National Heart, Lung, and Blood Institute, part of the NIH.
"Hydroxychloroquine has showed promise in a lab setting against SARS-CoV-2, the virus that causes COVID-19 and preliminary reports suggest potential efficacy in small studies with patients. However, we really need clinical trial data to determine whether hydroxychloroquine is effective and safe in treating COVID-19," he said.
While COVID-19 usually presents as an acute respiratory infectious illness, it can damage multiple organ systems, including heart, lung, and blood.
Advertisement
Hydroxychloroquine is used to treat malaria and rheumatoid conditions such as arthritis. In various studies, the drug has demonstrated antiviral activity, an ability to modify the activity of the immune system, said the NIH.
Advertisement
Source-IANS